Methods of monitoring conditions by sequence analysis

Patent metadata

Field	Value
Publication number	US-11001895-B2
Application number	US-201816222052-A
Country	US
Kind code	B2
Filing date	Dec 17, 2018
Priority date	Nov 7, 2008
Publication date	May 11, 2021
Grant date	May 11, 2021

Abstract

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.

First claim

The invention claimed is:

1. A method of assessing transplant rejection in an organ transplant recipient, comprising:
(a) amplifying molecules of nucleic acids comprising sequences of complementarity determining region 3 (CDR3) from T-cell receptor or B-cell receptor genes in a sample of lymphocytes obtained from the transplant recipient pre-transplant;
(b) isolating and sequencing the amplified molecules in the lymphocyte sample to provide a repertoire of CDR3 sequences comprising at least 1000 sequence reads of at least 30 bp;
(c) amplifying molecules of nucleic acids comprising sequences of CDR3 from T-cell receptor or B-cell receptor genes in a biopsy sample of the transplant graft obtained from the transplant recipient post-transplant;
(d) isolating and sequencing the amplified molecules in the biopsy sample to provide a repertoire of CDR3 sequences comprising at least 1000 sequence reads of at least 30 bp, and identifying correlating clonotypes more prevalent in the biopsy sample compared to the lymphocyte sample;
(e) amplifying molecules of nucleic acids comprising sequences of CDR3 from T-cell receptor or B-cell receptor genes in a blood sample obtained from the transplant recipient post-transplant;
(f) isolating and sequencing the amplified molecules in the blood sample to provide a repertoire of CDR3 sequences comprising at least 1000 sequence reads of at least 30 bp; and,
(g) assessing whether rejection of the transplant is occurring by confirming the presence and/or level of correlating clonotypes identified in step (d) among the sequences generated in step (f).

2. The method according to claim 1 , wherein each CDR3 sequence of each repertoire of CDR3 sequences includes one or more V segments and wherein the CDR3 sequence is amplified using primers specific to the one or more V segments.

3. The method according to claim 1 , wherein the correlating clonotypes identified in step (d) are distinguished from non-correlating clonotypes among the repertoires of CDR3 sequences by a comparison of the V, D and/or J segments of the CDR3 sequences in the repertoire provided in step (d) versus the repertoire provided in step (b).

4. The method according to claim 1 , wherein the CDR3 sequences have a level in each repertoire and wherein the correlating clonotypes identified in step (d) are distinguished from non-correlating clonotypes by a comparison of the level of the CDR3 sequences in the repertoire provided in step (d) versus the repertoire provided in step (b).

5. The method according to claim 1 , further comprising step (d) wherein the correlating clonotypes are further confirmed by comparison to clonotypes correlating to transplant rejection identified in lymphocyte samples obtained from other post-transplant subjects.

6. The method according to claim 1 , wherein the amplified molecules of nucleic acids are sequenced by synthesis using reversibly terminated labeled nucleotides.

7. The method according to claim 1 , wherein the T-cell receptor gene is a T-cell receptor gamma (TRG) gene.

8. The method according to claim 1 , wherein the T-cell receptor gene is a T-cell receptor beta (TRB) gene.

9. The method according to claim 1 , wherein the B-cell receptor gene is an IgH gene.

10. The method according to claim 1 , wherein the B-cell receptor gene is an IgK gene.

11. A method of quantitatively measuring clonotypes correlating to transplant rejection in an organ transplant recipient, comprising:
(a) amplifying molecules of nucleic acids comprising sequences of complementarity determining region 3 (CDR3) from T-cell receptor or B-cell receptor genes in a sample of lymphocytes obtained from the transplant recipient pre-transplant;
(b) isolating and sequencing the amplified molecules in the lymphocyte sample to provide a repertoire of CDR3 sequences comprising at least 1000 sequence reads of at least 30 bp;
(c) amplifying molecules of nucleic acids comprising sequences of CDR3 from T-cell receptor or B-cell receptor genes in a biopsy sample of the transplant graft obtained post-transplant;
(d) isolating and sequencing the amplified molecules in the biopsy sample to provide a repertoire of CDR3 sequences comprising at least 1000 sequence reads of at least 30 bp, and identifying clonotypes more prevalent in the biopsy sample compared to the lymphocyte sample as clonotypes correlating to transplant rejection; and
(e) producing a quantitative profile of clonotypes identified in step (d) that correlate to transplant rejection in the organ transplant recipient.

12. The method according to claim 11 , wherein each CDR3 sequence of each repertoire of CDR3 sequences includes one or more V segments and wherein the CDR3 sequence is amplified using primers specific to the one or more V segments.

13. The method according to claim 11 , wherein the correlating clonotypes identified in step (d) are distinguished from non-correlating clonotypes among the repertoires of CDR3 sequences by a comparison of the V, D and/or J segments of the CDR3 sequences in the repertoire provided in step (d) versus the repertoire provided in step (b).

14. The method according to claim 1 , wherein the CDR3 sequences have a level in each repertoire and wherein the correlating clonotypes identified in step (d) are distinguished from non-correlating clonotypes by the comparison of the level of the CDR3 sequences in the repertoire provided in step (d) versus the repertoire provided in step (b).

15. The method according to claim 11 , wherein the amplified molecules of nucleic acids are sequenced by synthesis using reversibly terminated labeled nucleotides.

16. The method according to claim 11 , wherein the T-cell receptor gene is a T-cell receptor gamma (TRG) gene.

17. The method according to claim 11 , wherein the T-cell receptor gene is a T-cell receptor beta (TRB) gene.

18. The method according to claim 11 , wherein the B-cell receptor gene is an IgH gene.

19. The method according to claim 1 , wherein the B-cell receptor gene is an IgK gene.

Assignees

• Adaptive Biotechnologies Corp

Inventors

• Faham Malek
• Willis Thomas

Classifications

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12N15/11 Primary

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6869 Primary

  Methods for sequencing · CPC title